Keros Therapeutics Inc
NASDAQ:KROS
| Market Cap (Intraday) | 1.18B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $43.91 |
| 50-Day MA | $51.82 |
| 200-Day MA | $42.65 |
Keros Therapeutics Inc Stock, NASDAQ:KROS
1050 Waltham Street, Suite 302, Lexington, Massachusetts 02421
United States of America
Phone: +1.617.314.6297
Number of Employees: 105
Description
Keros Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with unmet medical need. The company was founded in 2015 and is headquartered in Lexington, MA.